Nexalin Technologies Inc (NXL) Quote

$3+ soon🛫

Yet another after-the-breakout post by @Zardiw #DDAmanda.

Your video, you say, "there's an entry here because there's something going on with this stock."

Yet, you say so having the 'advantage' of Monday morning quarterbacking. You have the advantage of once only after you've done your scan you then are able to look and call out previous days' trading activity to claim you did a scsn previously... when you did not.

If you did, where was your previous DDAmanda post then that showed the activity, and that shows what you now after-the-breakout call, "there's an entry here because there's something going on with this stock."

Seems you're a bullshitter (a low level) scammer trying to trick people into purchasing your wwwaaaayyyy over priced $2,400 per year #DDAmanda software from a team of "we" (as you always say) that in actuality as a "we" in only you.

.

$NXL +211% #DDAmanda Video Analysis

#1 Stock Scanner/Screener



Z

thanks

NXL: "This is one GREAT LEAP for the trading account of iHub's mcnierney1 Fellow --- but one TINY STEP for the rest of iHub'ers everywhere!! HOUSTON, do you copy!!"

yes its awesome just the start

NXL: Well then, Dude, tell us all what it's LIKE up there!!! (I missed this one ENTIRELY!!)

NXL: What-the-FLUCK??!!! (Rather LATE price reaction to their yesterday PR!!)

Crazy volume

NXL..........https://stockcharts.com/h-sc/ui?s=NXL&p=W&b=5&g=0&id=p86431144783

getting prepared to go to the moon only a foolish investor would not think so!

Strong buy this will triple in my opinion

NXL: Could you please ELABORATE a little beyond simply, "DAMN"???

Damn

strong buy!! So many mental health disorders will be helped and tbi will be helped

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Source: GlobeNewswire Inc.?

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices.
Mark White, CEO of Nexalin Technology, stated, "We are pleased to announce approval to sell our Gen-2 neurostimulation device in Brazil, which represents our second regulatory approval outside of China since the start of this year.  Brazil is an important market as it represents the 9th largest economy in the world with a population in excess of 215 million.  Among this population, more than 35 million are afflicted with mental health disorders. Moreover, this approval is an important springboard into other markets within South America.  We are rapidly advancing discussions with a key distributor in this market and look forward to providing further updates.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device was recently approved in Oman and China.  Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
NXL@redchip.com

Yikes

NXL...grabbed a few @ 2.38

lol

NXL: I do get in my CLOWN moods, occasionally. (Right now, I have to CHANGE my iHub Profile Picture --- to reflect my TRUE inner spirit!!!)

NXL: HA-HAAAAA!!! Why not???

NXL: Hey, and THANKS again for the selfie video clip of YOU (below), working your latest "AI-MARKETS-SCANNER"!!!


"I see a price CORRECTION looming in precisely 15-seconds on NXL --- prepare to abort the play!!! And reload to FLIP-IT again!!!"

I MAY NEED TO USE ONE OF THEIR HEAD BANDS FOR TAKING THIS OFF MY SCREEN

LOL..YOU MAKE ME LAUGH DUDE

NXL: Hey, Dude, I FOLLOW your posts everyday --- like a Police Dog on a short leash!!!

MARKET CORRECTION IS HERE

LMAO...LUV YOU DUDE...CAN'T BELIEVE I WAS THE FIRST HERE AND FIRST TO GO....IDIOT I AM!

NXL: Hey there, Lord T-T-2016, Dude!!! What-the-fluck is goin' on today, Homeboy --- across the Wall Street MARKETOS!!!

PS: The LEAD GUITAR RIFT in that Pat Benetar song is OFF-THE-SPECTRUM, Bro!! That guitar dude hits a NOTE therein that is from another GALAXY!!!


(Let the above run, until that LEAD GUITAR does his stuff!!!)

LMAO...FLEET COMANDO!!!!

NXL: This is the Fleet Commander to all NXL Company warships --- FIRE-AT-WILL!!!

Nope, that monster number there was NOT me dumping my @VVPR --- but that WAS an easy & quick flip, for my little (late Pre-M) 'Lotto Ticket' behind it.

VVPR

Not sure WHICH stock you are referring to, Capt. TIm.

2M FLOAT,LOOK AT THE BIG DUMP***18M ONE TIME, THATMUSTBEYOU

@AINC merely the old ploy, 'We ain't gonna dump more shares on ya, America, so make our stock SOAR now!!' (And @VVPR a nice quip FLIP, right out the starting gate today, Dude!!!)

ADTX,VVPR, AINC e.t.c

NXL: Told ya so!!!! To dah MOON!!!

NXL: Watch out!! They gots some BONKERS Electromagnetic GADGETS at the NXL Firm!!! (See ME, below, using one their disruptive new "Post-Traumatic-STUPIDITY-Disorder", deep-Brain, stimulators during routine brushing of my teeth!!!)

you were right

Closed up 50% … Expecting continuation going north tomorrow… IMO

A real micro beast. The product pipeline is amazing!

NXL..THIN....HERE WE GO

NXL...HERE WE GO

NXL...BLOWING UP

NXL...MICRO BEAST

Nice news… Took a position

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures

Agreed

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device